Lumida
/CLPT
⌘K
Clearpoint Neuro Inc

Clearpoint Neuro Inc

CLPT
$13.72USD+1.78%+0.24 today

MARKET CAP

418.5M

P/E (TTM)

FWD P/E

DAY RANGE

$13 – $14

52W RANGE

$8
$30

AI Summary

Stalk
StalkMedium

CLPT remains in a Stage 2 advancing corrective reset with clear higher highs and higher lows. Price is currently extended above rising short-term EMAs and in extreme overbought territory, and the late-June bearish exhaustion candle signals waning upside momentum and a likely pullback. Under a Speculative strategy, high asymmetry and defined structure are required, so patience is advised. A pullback toward the 9/21 EMA zone offers a more favorable entry for continuation participation.

  • Q2 revenue $10.9M (+18% YoY), signaling sustained product demand.
  • New 30k ft² lab (CAL) to expand capacity, targeting >$60M rev.
  • H1 operational cash burn of $15M reduced cash reserves to $29.4M.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$16.3M$20.6M$24.0M$31.4M$37.0M
YoY %+27.0%+26.1%+16.6%+31.0%+17.8%
P / Sales14.3x9.8x6.9x13.2x10.5x
EV / Sales12.0x9.4x6.9x13.0x11.1x
Gross Profit, Adj.$11.1M$13.5M$13.6M$19.1M$22.7M
YoY %+22.0%+21.6%+0.6%+40.5%+18.7%
Margin %68.2%65.8%56.8%60.9%61.4%
EV / Gross Profit17.6x14.2x12.1x21.4x18.1x
EBITDA, Adj.$-12.7M$-15.6M$-22.4M$-17.8M$-21.9M
YoY %-123.7%-22.7%-44.3%+20.6%-23.0%
Margin %-77.8%-75.7%-93.7%-56.8%-59.3%
EV / EBITDA-15.4x-12.4x-7.3x-23.0x-18.8x
EBIT$-13.4M$-16.3M$-22.4M$-19.7M$-24.2M
YoY %-115.0%-22.1%-37.4%+12.1%-22.4%
Margin %-82.1%-79.5%-93.7%-62.9%-65.4%
EV / EBIT-14.6x-11.8x-7.3x-20.7x-17.0x
Net Income$-14.4M$-16.4M$-22.1M$-18.9M$-25.5M
YoY %-112.5%-14.1%-34.4%+14.4%-35.0%
Net Margin-88.4%-80.0%-92.2%-60.3%-69.1%
EPS (GAAP)-$0.69-$0.68-$0.90-$0.70-$0.90
YoY %-60.5%+1.4%-32.4%+22.2%-28.6%